In recent years, serum uric acid (SUA) as a determinant of cardiovascular (CV) risk has gained interest. Epidemiological, experimental and clinical data show that patients with hyperuricaemia SUA are at increased risk of cardiac, renal and vascular damage and CV events. There is now some evidence to suggest that urate-lowering treatment may reduce CV risk in this group and, thus, may represent a new strategy in risk reduction.
Uric acid and cardiovascular disease: An update
Muiesan M. L.;Agabiti-Rosei C.;Paini A.;Salvetti M.
2016-01-01
Abstract
In recent years, serum uric acid (SUA) as a determinant of cardiovascular (CV) risk has gained interest. Epidemiological, experimental and clinical data show that patients with hyperuricaemia SUA are at increased risk of cardiac, renal and vascular damage and CV events. There is now some evidence to suggest that urate-lowering treatment may reduce CV risk in this group and, thus, may represent a new strategy in risk reduction.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2016 Uric acid review.pdf
gestori archivio
Tipologia:
Full Text
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
144.21 kB
Formato
Adobe PDF
|
144.21 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
